- Forums
- ASX - By Stock
- MSB
- Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-58
-
- There are more pages in this discussion • 790 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.40 |
Change
-0.060(4.12%) |
Mkt cap ! $1.598B |
Open | High | Low | Value | Volume |
$1.43 | $1.43 | $1.39 | $2.033M | 1.450M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 35899 | $1.40 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.40 | 24692 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 15772 | 1.400 |
11 | 51693 | 1.395 |
25 | 178885 | 1.390 |
18 | 151342 | 1.385 |
30 | 262817 | 1.380 |
Price($) | Vol. | No. |
---|---|---|
1.405 | 29354 | 18 |
1.410 | 54841 | 12 |
1.415 | 50680 | 7 |
1.420 | 48645 | 7 |
1.425 | 87156 | 5 |
Last trade - 12.16pm 16/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online